SensAbues AB is a healthtech company specializing in drug detection and health monitoring technology. Founded in 2010 as a spin-out from the prestigious Karolinska Institute, SensAbues aims to commercialize the innovative discovery of a new exhaled breath sampling biomatrix known as EB. This lab-based method utilizes chromatographic-mass spectrometry or polymerase chain reaction techniques to detect the presence of non-volatile exogenous substances in the blood by capturing bioaerosol particles released through exhaled breath.

SensAbues has developed EB into a comprehensive and flexible platform that offers a non-invasive procedure for biological sample collection, specimen preparation, and testing. With over 20,000 drug tests performed using this technique in Scandinavia alone, EB has successfully detected more than 80 substances and metabolites. Extensive lab studies and field trials have generated a wealth of data to support the scientific validation of EB.

Beyond workplace drug testing, EB is also utilized in various settings, including high schools, criminal justice systems, substance abuse clinics, and hospital A&E departments. It is actively being evaluated for therapeutic drug monitoring, medication adherence tracking, metabolomics studies, and biomarker determination. The low cost and non-invasive nature of this method make it particularly suitable for telemedicine, remote care applications, and drug kinetics studies in resource-poor locations.

One of the key advantages of SensAbues is its ability to provide a new biomatrix alongside a comprehensive methodology, setting the company apart from its competitors. SensAbues focuses on collaborative partnerships to maximize its technology's potential within existing markets and to develop innovative solutions for emerging applications. With its groundbreaking approach, SensAbues is at the forefront of revolutionizing drug detection and health monitoring worldwide